RET and non-small cell lung carcinoma: Although selective RET inhibitors are well tolerated and induce significant and durable tumor responses in heavily pretreated patients with RET-rearranged NSCLC, however, as has been seen with other selective TKIs, the emergence of acquired resistance may limit long-term efficacy.